ROLIVER - Prospective Cohort for the Identification of Liver Microbiota
NCT03511573 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36
Last updated 2018-04-30
Summary
The existence of an adipose tissue microbiota causally involved in the triggering of a low grade inflammation could resemble what observed in liver fibrosis. To generate microbial hypotheses putatively responsible for the onset of liver fibrosis we sequenced the 16SrDNA gene from liver biopsies from 36 obese patients (ROLIVER cohort) and describe an original mathematical approach to decipher signatures of early stage of liver fibrosis F0, F1, F2.
Conditions
- To Generate Microbial Hypotheses Putatively Responsible for the Onset of Liver Fibrosis
Interventions
- PROCEDURE
-
bariatric and other laparoscopic surgery
We have obtained liver samples during laparoscopic surgical procedures in the majority of cases. The majority of laparoscopic procedures were sleeve gastrectomies performed for morbid obesity as a primary restrictive procedure; in 5 cases the liver biopsies were performed during laparoscopic cholecystectomies.
Sponsors & Collaborators
-
Tîrgu Mureș Emergency Clinical County Hospital, Romania
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-01-01
- Primary Completion
- 2016-12-31
- Completion
- 2017-01-31
More Related Trials
-
Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis
NCT06533852 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis
NCT06478602 ·Status: COMPLETED ·Phase: PHASE3
-
Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
NCT02400216 ·Status: COMPLETED
-
Fecal Microbiota Transplantation for Liver Failure
NCT05170971 ·Status: RECRUITING ·Phase: NA
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
NCT05045482 ·Status: RECRUITING ·Phase: PHASE1
-
Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD
NCT06495333 ·Status: RECRUITING
-
Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease
NCT05209100 ·Status: COMPLETED
-
A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function
NCT06340347 ·Status: COMPLETED ·Phase: PHASE1
-
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
NCT03957070 ·Status: COMPLETED ·Phase: NA
-
Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy
NCT04155099 ·Status: TERMINATED ·Phase: PHASE2
-
Probiotics in NASH Patients - PROBILIVER TRIAL
NCT03467282 ·Status: UNKNOWN ·Phase: NA
-
Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study
NCT02469272 ·Status: UNKNOWN ·Phase: PHASE1
-
Lanreotide as Treatment of Polycystic Livers
NCT00565097 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain
NCT07191704 ·Status: RECRUITING
-
Investigation of Synbiotic Treatment in NAFLD
NCT01680640 ·Status: COMPLETED ·Phase: NA
-
Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis
NCT05863364 ·Status: RECRUITING ·Phase: NA
-
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
NCT03479125 ·Status: TERMINATED
-
Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy
NCT02019784 ·Status: COMPLETED ·Phase: PHASE4
-
Probiotics in the Treatment of NAFLD
NCT02764047 ·Status: UNKNOWN ·Phase: NA
-
Effect of Probiotic and Smectite Gel on NAFLD
NCT03614039 ·Status: COMPLETED ·Phase: NA
-
An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis
NCT02174367 ·Status: UNKNOWN
-
Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
NCT00856869 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development
NCT03780673 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of Saccharomyces Boulardii in Patients in the Waiting List for Liver Transplant
NCT01762748 ·Status: COMPLETED ·Phase: PHASE2
-
Rifaximin in Fatty Liver Disease
NCT01355575 ·Status: TERMINATED ·Phase: PHASE4